ClearPoint Neuro, Inc. Announces Installation of ClearPoint® 2.0 Software at Mazowiecki Szpital Bródnowski in Poland
SOLANA BEACH, Calif., June 16, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced the installation of its version 2.0 software at Mazowiecki Szpital Bródnowski in Warsaw, Poland.
“We appreciated the patience and commitment of the on-site ClearPoint team throughout the installation process,” stated Professor Mirosław Ząbek, Head of the Neurosurgery Clinic at Mazowiecki Szpital Bródnowski. “Our entire team is looking forward to begin performing DBS, biopsy and clinical trial cases with the ClearPoint Neuro Navigation System.”
“Dr. Ząbek and his team have been involved in cutting-edge drug delivery protocols for many years,” commented Matt Rabon, Clinical and Business Development Manager, EMEA. “Poland is one of the largest clinical trial markets in Central Eastern Europe with highly qualified investigators and specialized medical centers. It will be a great honor to support both clinical procedures and investigational trials at this prestigious hospital. This is another example of us executing our strategy to set up ClearPoint biologic and drug delivery trial centers across Europe. Now that COVID seems to be receding in Europe, we expect these installations to continue in the second half of 2021.”
About ClearPoint Neuro
ClearPoint Neuro’s mission is to improve and restore quality of life to patients and their families by enabling therapies for the most complex neurological disorders with pinpoint accuracy. Applications of the Company’s current product portfolio include deep brain stimulation, laser ablation, biopsy, neuro-aspiration, and delivery of drugs, biologics, and gene therapy to the brain. The ClearPoint Neuro Navigation System has FDA clearance, is CE-marked, and is installed in over 60 active sites in the United States, Canada, and Europe. ClearPoint Neuro is partnered with over 30 biologics/pharmaceutical companies and academic centers, providing solutions for direct CNS delivery of therapeutics in pre-clinical studies and clinical trials worldwide. To date, more than 4,500 cases have been performed and supported by the Company’s field-based clinical specialist team, which offers support and services to our customers and partners. For more information, please visit www.clearpointneuro.com.
Statements herein concerning the Company’s plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. Uncertainties and risks may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: the impact of COVID-19 and the measures adopted to contain its spread; future revenues from sales of the Company’s ClearPoint Neuro Navigation System products; and the Company’s ability to market, commercialize and achieve broader market acceptance for the Company’s ClearPoint Neuro Navigation System products. More detailed information on these and additional factors that could affect the Company’s actual results are described in the “Risk Factors” section in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, and the Company’s Quarterly Report on Form 10-Q for the three months ended March 31, 2021, both of which have been filed with the Securities and Exchange Commission.To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Biotalys announces end of Stabilization Period and the partial exercise of the Over-allotment Option in respect of 712,942 Shares in connection with its Initial Public Offering2.8.2021 07:00:00 CEST | Press release
Ghent, BELGIUM, Aug. 02, 2021 (GLOBE NEWSWIRE) -- This announcement is not an offer to invest in the shares (the “Shares”) of Biotalys. An investment in the Shares can only be based on the prospectus (the “Prospectus”) Biotalys has issued in connection with the offering of its Shares and which has, subject to the certainlimitations, been made available on the Company’s website atwww.biotalys.com/investorsand prospective investors must read the entire prospectus in order to fully understand the potential risks and rewards associated with the decision to invest in the Shares. Prospective investors should read in particular the section on “Risk Factors” for a discussion of certain factors which should be considered in connection with an investment in the Shares, includingthe following risks: (i) Biotalys has never brought a product to the market. All but one of Biotalys’ product candidates are still in early stages of discovery. Only one product candidate is in the registration phase, but
TGS Announces NOAKA Ocean Bottom Node Seismic Survey on the Norwegian Continental Shelf2.8.2021 07:00:00 CEST | Press release
OSLO, Norway (2 August 2021) - TGS, a global provider of energy data and intelligence, today announced a new Ocean Bottom Node (OBN) seismic survey on the Norwegian Continental Shelf (NCS). The 437 square kilometer survey will be acquired in the NOAKA area, between Oseberg and Alvheim in the Norwegian North Sea, containing both held and open acreage. This region has seen significant Infrastructure-Led Exploration (ILX) activity in recent years and includes the development of the NOAKA fields, one of the largest developments on the NCS, with recoverable reserves of more than 500 million barrels of oil equivalents. TGS expects to emulate the recent success of the TGS-AGS Utsira OBN project in the North Sea (the first large-scale, densely sampled OBN survey for exploration) and will apply the learnings from TGS’ ongoing reprocessing of Utsira, including the extraction and use of ultra-long offset signal for FWI-based model building. As with Utsira, the NOAKA survey will utilize full azimu
Yara continues its transformation with divestment of Salitre phosphate mining project in Brazil1.8.2021 21:00:00 CEST | Press release
Oslo, 1 August 2021: Yara has signed a Share Purchase Agreement with EuroChem to sell its Salitre phosphate mining project for a cash consideration of USD 410 million. Yara’s ongoing transformation has a strategic focus on food solutions, premium products and enabling the hydrogen economy. Salitre remains an attractive project, but as previously communicated the project progress has been impacted by Covid 19, and significant construction time and capital expenditure remains to reach completion. The Salitre divestment therefore supports Yara’s transformation by reallocating capital and risk appetite in the coming years towards Yara’s strategic focus areas. “This transaction allows us to further sharpen our strategic focus, based on our strong competitive edges. Yara Brazil will continue to play an essential role in this growth agenda, and this transaction enables that growth to be driven with a sharper downstream focus,” said Svein Tore Holsether, President and Chief Executive Officer o
Scientists Narrow Search For Mysterious Mad Trapper To Sweden30.7.2021 23:21:41 CEST | Press release
EDMONTON, Alberta and HOUSTON, July 30, 2021 (GLOBE NEWSWIRE) -- This month marks the 90th anniversary of the arrival of the fugitive known as ‘The Mad Trapper of Rat River’ to the Canadian North and the revelation of an important new clue to identifying the mysterious fugitive. Following the unprovoked shooting of RCMP Constable A.W. King in December 1931, the unknown criminal who identified himself by the pseudonym Albert Johnson led an RCMP posse on seven-week manhunt across the desolate Arctic landscape. During the pursuit, the Mad Trapper shot and killed Constable E. Millen. With the help of indigenous guides the Mad Trapper was located and killed during a gun battle on the Eagle River on February 17, 1932. Despite the RCMP releasing photos of the Mad Trapper and receiving hundreds of tips from around the world his identity was never established In 2007, Myth Merchant Films of Alberta Canada secured permission for a team of forensic experts to exhume the body of the Mad Trapper in
KBC Group: KBC remains strongly capitalised under 2021 EU-wide EBA stress test30.7.2021 18:15:00 CEST | Press release
Press Release Outside trading hours - Regulated information* Brussels, 30 July 2021 (6.15 p.m. CEST) KBC remains strongly capitalised under 2021 EU-wide EBA stress test KBC notes the announcements made today by the European Banking Authority (EBA) regarding the results of the 2021 EU-wide stress test. A brief set of slideson the KBC data is available at www.kbc.com. The impact of the stress test on KBC’s fully loaded Common Equity Tier-1 (CET1) ratio of 17.58% at year-end 2020 caused this ratio to increase by 1.92 percentage points to 19.50% at year-end 2023 under the base scenario. Under the adverse scenario, KBC’s fully loaded CET1 ratio would fall by 3.51 percentage points to 14.07%1. KBC’s leverage ratio, which stood at 6.42% at year-end 2020, would increase to 7.09% under the base scenario and decrease to just 5.53% under the adverse scenario. Commenting on today’s announcements, Johan Thijs, KBC Group CEO had this to say: ‘The results of this regular, theoretical exercise conduct
EBA reports on outcome of 2021 EU-wide stress test30.7.2021 18:10:23 CEST | Press release
EBA reports on outcome of 2021 EU-wide stress test ING Group was subject to the 2021 EU-wide stress test conducted by the European Banking Authority (EBA), in cooperation with the European Central Bank (ECB), the European Systemic Risk Board (ESRB) and De Nederlandsche Bank. ING Group notes the announcements made today by the EBA on the stress test and fully acknowledges the outcomes of this exercise. The 2021 EU-wide stress test does not contain a pass/fail threshold and instead is designed to be used as an important source of information for the purposes of the Supervisory Review and Evaluation Process. The results will assist competent authorities in assessing ING Group’s ability to meet applicable prudential requirements under stressed scenarios. The adverse stress test scenario was set by the ECB/ESRB and covers a three-year time horizon (2020-2023). The stress test has been carried out applying a static balance sheet assumption as at December 2020, and therefore does not take int
Marc Peeters, new member in supervisory board of Intervest Offices & Warehouses30.7.2021 18:00:00 CEST | Press release
The supervisory board of Intervest has co-opted ir. Marc Peeters to take up a mandate with effect from 1 August 2021 as an independent member of the supervisory board. His final appointment will be proposed at the next general meeting of Intervest. Attachment New member supervisory board